19 Mar , 2025 By : Debdeep Gupta
Zydus Lifescience's share price extended the gains on the third consecutive session on March 19, rising more than 1 percent after the company received final approval from USFDA for Apalutamide Tablets, 60 mg.
At 09:20 am, Zydus Lifesciences was quoting at Rs 916.05, up Rs 12.95, or 1.43 percent, on the BSE.
".....has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Apalutamide Tablets, 60 mg (Erleada Tablets, 60 mg).
Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer. The tablets will be produced at the Ahmedabad facility, it added.
On March 16, the company received final approval from the USFDA to manufacture Eluxadoline Tablets, 75 mg and 100 mg. Eluxadoline is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
On March 14, the company informed that the USFDA conducted a surveillance inspection at the group’s API Unit 1, located at Ankleshwar in Gujarat. The inspection was conducted from March 10th to 14th, 2025, and concluded with NIL observations.
On March 12, the company received final approval from the USFDA to manufacture Methenamine Hippurate Tablets USP, 1 gram, indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary.
Also company's venture capital arm Zynext Ventures USA LLC announced its investment in Illexcor Therapeutics (Illexcor), a pioneering biopharmaceutical company developing next-generation oral therapies for sickle cell disease (SCD).
0 Comment